Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mythili Shastry

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Breast Cancer Research and Treatment|February 16, 2020
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapyDenise A Yardley, Nancy Peacock, Brooke Daniel, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Clinical Breast Cancer|November 26, 2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Denise A Yardley, Robyn R Young, Kerin B Adelson, et al.
Journal of Neuro-Oncology|August 9, 2019
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)John D Hainsworth, Kevin P Becker, Tarek Mekhail, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Breast Cancer Research and Treatment|February 16, 2020
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapyDenise A Yardley, Nancy Peacock, Brooke Daniel, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Clinical Breast Cancer|November 26, 2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Denise A Yardley, Robyn R Young, Kerin B Adelson, et al.
Journal of Neuro-Oncology|August 9, 2019
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)John D Hainsworth, Kevin P Becker, Tarek Mekhail, et al.
Pageof 3